<DOC>
	<DOCNO>NCT01567735</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability TMC435 combination Peginterferon alfa-2a ( PegINF alfa-2a ) ribavirin ( RBV ) treatment-naïve treatment experience , chronic hepatitis C ( HCV ) virus , genotype-4 infected patient .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety Tolerability TMC435 Combination With PegIFN Alfa-2a ( Pegasys ) Ribavirin ( Copegus ) Treatment-Naïve Treatment-Experienced , Chronic Hepatitis C Virus Genotype-4 Infected Patients</brief_title>
	<detailed_description>This open-label ( participant investigator know name medication give certain moment ) , single arm Phase III study , 3 subpopulation : treatment naive , previous HCV relapser previous HCV non-responders . The study consist 3 phase : screen phase maximum 6 Weeks , open-label treatment phase 24 48 Weeks treatment naive patient relapsers ( response guide treatment ) 48 Weeks non-responders , follow 24 Week follow-up period . The duration participation study individual participant 54 78 ( include screen ) . Part Ia : All participant receive 12 Weeks triple therapy TMC435 ( 150mg daily [ q.d . ] ) , PegINF-alfa-2a ( 180µg per Week ) RBV ( 1000 1200 mg per day , base weight ) , follow 12 Weeks PegINF-alfa-2a ( 180µg per Week ) RBV ( 1000 1200 mg per day , base weight ) . Part Ib : Participants need continue treatment another 24 Weeks ( non-responders + treatment naive relapser patient need continue treatment accord response guide treatment criterion ) receive additional 24 Weeks PegINF-alfa 2a ( 180 mg per Week ) RBV ( 1000 1200 mg per day , base weight ) . Part II : 24 Week follow-up period participant , start Week 24 Week 48 . In Part Ia , participants come 6 visit first month , follow visit every month Week 24 ( total 11 visits- Day1 , day 3 , Day 7 , Day 14 , day 28 , Week 8 , Week 12 , Week 16 , Week 20 Week 24 ) safety , efficacy tolerability check . In Part Ib , participants come 4 additional visit ( Week 28 , Week 36 , Week 42 Week 48 ) safety , tolerability efficacy check In follow-up period , participant come additional 3 visit ( either Week 28 , Week 36 Week 28 Week 52 , Week 60 Week 72 ) safety efficacy check . Participants withdraw prematurely visit withdrawal , 4 Weeks withdrawal every 12 Weeks 72 Weeks baseline safety check .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Genotype 4 Hepatitis C virus ( HCV ) infection ( confirmed screening ) Plasma HCV ribonucleic acid ( RNA ) &gt; 10,000 IU/mL screen Participants either treatmentnaïve treatmentexperienced ( nonresponder relapser ) adequate documentation previous response Participants must voluntarily sign Informed Consent Form ( ICF ) indicate understand purpose procedure require study willing participate study . To participate optional pharmacogenomic component study ( exploratory host genotyping ) , participant must voluntarily sign separate ICF component ( local regulation permit ) . Refusal give consent component exclude participant participation core study . Participants must liver biopsy within 3 year prior screen ( screen baseline visit ) histology consistent chronic HCV infection Has infection/coinfection nongenotype 4 HCV Has coinfection Human Immunodeficiency Virus ( HIV ) type 1 type 2 ( HIV1 HIV2 ) ( positive HIV1 HIV2 antibodies test screen ) . Has follow laboratory abnormality : 1 . Platelet count &lt; 90,000/mm3 ; 2 . Absolute neutrophil count ( ANC ) &lt; 1500 cells/mm3 ( Blacks : &lt; 1200 cells/mm3 ) ; 3 . Hemoglobin &lt; 12 g/dL woman &lt; 13 g/dL men ; 4 . Creatinine &gt; 1.5 mg/dL ; 5 . ALT and/or AST &gt; 10 x upper limit normal ( ULN ) ; 6 . Total serum bilirubin &gt; 1.5 x ULN ; 7 . Alphafetoprotein [ AFP ] &gt; 50 ng/mL ; 8 . Albumin plasma concentration &lt; 3.5 g/dL ; 9 . Prothrombin time ( PT ) express international normalized ratio ( INR ) &gt; 1.5 . Note : retesting abnormal laboratory value lead exclusion allow use unscheduled visit screen period assess eligibility . Used disallow concomitant therapy Has evidence hepatic decompensation ( history current evidence ascites , bleed varix hepatic encephalopathy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>TMC435HPC3011</keyword>
	<keyword>TMC435</keyword>
</DOC>